PriceTargets.com logo

Zealand Pharma A/S - ZLDPF Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$100.51 As of 12/20/2024 06:55 PM ET
▲ +0.71 (0.71%)

This chart shows the closing price for ZLDPF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Zealand Pharma A/S Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ZLDPF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ZLDPF

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 3 analysts offering 12 month price targets for Zealand Pharma A/S in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $100.51.

This chart shows the closing price for ZLDPF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 3 polled investment analysts is to buy stock in Zealand Pharma A/S. This rating has held steady since October 2023, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/2/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/29/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/28/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/26/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/24/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/23/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/23/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/8/2024JPMorgan Chase & Co.Initiated CoverageOverweight
5/21/2024Cantor FitzgeraldInitiated CoverageOverweight
3/7/2024BTIG ResearchInitiated CoverageBuy
11/16/2022Morgan StanleyDowngradeOverweight ➝ Equal Weight
1/11/2022Jefferies Financial GroupUpgradeHold ➝ Buy
(Data available from 12/23/2019 forward)

News Sentiment Rating

-0.04 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/27/2024
  • 4 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/26/2024
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/26/2024
  • 2 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/25/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/24/2024
  • 1 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/24/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/23/2024
  • 1 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
12/23/2024

Current Sentiment

  • 1 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
Zealand Pharma A/S logo
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.
Read More

Today's Range

Now: $100.51
Low: $95.50
High: $100.99

50 Day Range

MA: $111.30
Low: $94.24
High: $126.00

52 Week Range

Now: $100.51
Low: $50.65
High: $141.74

Volume

1,272 shs

Average Volume

1,935 shs

Market Capitalization

$5.18 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.89

Frequently Asked Questions

What sell-side analysts currently cover shares of Zealand Pharma A/S?

The following Wall Street analysts have issued stock ratings on Zealand Pharma A/S in the last twelve months: BTIG Research, Cantor Fitzgerald, and JPMorgan Chase & Co..
View the latest analyst ratings for ZLDPF.

What is the current price target for Zealand Pharma A/S?

0 Wall Street analysts have set twelve-month price targets for Zealand Pharma A/S in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Zealand Pharma A/S in the next year.
View the latest price targets for ZLDPF.

What is the current consensus analyst rating for Zealand Pharma A/S?

Zealand Pharma A/S currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ZLDPF will outperform the market and that investors should add to their positions of Zealand Pharma A/S.
View the latest ratings for ZLDPF.

What other companies compete with Zealand Pharma A/S?

Other companies that are similar to Zealand Pharma A/S include 180 Life Sciences, 4D pharma, 4Front Ventures, Abattis Bioceuticals and Aeolus Pharmaceuticals. Learn More about companies similar to Zealand Pharma A/S.

How do I contact Zealand Pharma A/S's investor relations team?

Zealand Pharma A/S's physical mailing address is Sydmarken 11 Soborg, Copenhagen G7, 2860. The company's listed phone number is 45-8877-3600 and its investor relations email address is [email protected]. The official website for Zealand Pharma A/S is www.zealandpharma.com. Learn More about contacing Zealand Pharma A/S investor relations.